213 related articles for article (PubMed ID: 28846180)
1. Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells.
Kutkowska J; Strzadala L; Rapak A
Cancer Sci; 2017 Nov; 108(11):2265-2272. PubMed ID: 28846180
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.
Giovannetti E; Labots M; Dekker H; Galvani E; Lind JS; Sciarrillo R; Honeywell R; Smit EF; Verheul HM; Peters GJ
Curr Pharm Des; 2013; 19(5):927-39. PubMed ID: 22973961
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia increases the apoptotic response to betulinic acid and betulin in human non-small cell lung cancer cells.
Kutkowska J; Strzadala L; Rapak A
Chem Biol Interact; 2021 Jan; 333():109320. PubMed ID: 33181113
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib in Combination with Betulinic Acid Synergistically Induces Cell Cycle Arrest and Inhibits Clonogenic Activity in Pancreatic Ductal Adenocarcinoma Cells.
Kutkowska J; Strzadala L; Rapak A
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347681
[TBL] [Abstract][Full Text] [Related]
5. Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.
Paz-Ares L; Hirsh V; Zhang L; de Marinis F; Yang JC; Wakelee HA; Seto T; Wu YL; Novello S; Juhász E; Arén O; Sun Y; Schmelter T; Ong TJ; Peña C; Smit EF; Mok TS
J Thorac Oncol; 2015 Dec; 10(12):1745-53. PubMed ID: 26743856
[TBL] [Abstract][Full Text] [Related]
6. Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.
Pasqualetti G; Ricciardi S; Mey V; Del Tacca M; Danesi R
Lung Cancer; 2011 Nov; 74(2):197-205. PubMed ID: 21529991
[TBL] [Abstract][Full Text] [Related]
7. Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis.
Chen C; Ju R; Shi J; Chen W; Sun F; Zhu L; Li J; Zhang D; Ye C; Guo L
J Pharmacol Exp Ther; 2017 Aug; 362(2):219-229. PubMed ID: 28515157
[TBL] [Abstract][Full Text] [Related]
8. Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.
Caiola E; Frapolli R; Tomanelli M; Valerio R; Iezzi A; Garassino MC; Broggini M; Marabese M
Sci Rep; 2018 Jan; 8(1):948. PubMed ID: 29343688
[TBL] [Abstract][Full Text] [Related]
9. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.
Dingemans AM; Mellema WW; Groen HJ; van Wijk A; Burgers SA; Kunst PW; Thunnissen E; Heideman DA; Smit EF
Clin Cancer Res; 2013 Feb; 19(3):743-51. PubMed ID: 23224737
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
Groenendijk FH; Mellema WW; van der Burg E; Schut E; Hauptmann M; Horlings HM; Willems SM; van den Heuvel MM; Jonkers J; Smit EF; Bernards R
Int J Cancer; 2015 Mar; 136(6):1434-44. PubMed ID: 25080865
[TBL] [Abstract][Full Text] [Related]
12. A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
Lim SM; Cho BC; Kim SW; Kang SY; Heo DS; Kim HT; Lee DH; Kim DW; Jung M; Choi JH; Shim HS; Choi JR; Kim JH
Lung Cancer; 2016 Mar; 93():1-8. PubMed ID: 26898607
[TBL] [Abstract][Full Text] [Related]
13. Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells.
Ko JL; Lin CH; Chen HC; Hung WH; Chien PJ; Chang HY; Wang BY
Environ Toxicol; 2018 Nov; 33(11):1153-1159. PubMed ID: 30136359
[TBL] [Abstract][Full Text] [Related]
14. Rhabdomyosarcoma cells are susceptible to cell death by LDK378 alone or in combination with sorafenib independently of anaplastic lymphoma kinase status.
Dolgikh N; Fulda S
Anticancer Drugs; 2017 Nov; 28(10):1118-1125. PubMed ID: 29045271
[TBL] [Abstract][Full Text] [Related]
15. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.
Li J; Chen Y; Wan J; Liu X; Yu C; Li W
Br J Pharmacol; 2014 Jul; 171(13):3182-95. PubMed ID: 24571452
[TBL] [Abstract][Full Text] [Related]
16. Co-treatment of betulin and gefitinib is effective against EGFR wild-type/KRAS-mutant non-small cell lung cancer by inducing ferroptosis.
Yan WY; Cai J; Wang JN; Gong YS; Ding XB
Neoplasma; 2022 May; 69(3):648-656. PubMed ID: 35330996
[TBL] [Abstract][Full Text] [Related]
17. Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
Zhang H; Li Z; Wang K
Oncol Rep; 2014 Apr; 31(4):1954-60. PubMed ID: 24549815
[TBL] [Abstract][Full Text] [Related]
18. Alteration in the balance of prosurvival and proapoptotic signalling pathways leads to sequence-dependent synergism between docetaxel and sorafenib in human non-small cell lung cancer cell lines.
He X; Zhang T
Cell Biochem Biophys; 2014 Mar; 68(2):411-8. PubMed ID: 23990130
[TBL] [Abstract][Full Text] [Related]
19. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
[TBL] [Abstract][Full Text] [Related]
20. (Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.
Schneider TC; Kapiteijn E; van Wezel T; Smit JWA; van der Hoeven JJM; Morreau H
BMC Cancer; 2016 Jan; 16():31. PubMed ID: 26786320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
